A Phase II Window of Opportunity Trial With GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

Trial Profile

A Phase II Window of Opportunity Trial With GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2016

At a glance

  • Drugs Trametinib (Primary)
  • Indications Oropharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 03 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top